Seeking Alpha

Novavax gains on continued optimism over its RSV vaccine

  • Novavax (NVAX +4.9%) gains on renewed optimism that the company may announce positive news on its Respiratory Syncytial Virus Fusion Vaccine at its annual Analyst Day on September 24.
  • Last week Lazard upped its price target on the shares to $11, saying the vaccine was "one of the more under-appreciated assets in the industry."
  • The firm thinks NVAX's drug could be more effective than its competitor, Synagis.
  • Additionally, Italian veterinary authorities have reported an outbreak of highly pathogenic avian influenza at a commercial poultry farm in Emilia-Romagna, an administrative region in Northern Italy.
Comments (1)
  • Scrying Biotech
    , contributor
    Comments (1535) | Send Message
    ScryingBiotech, fortell the future -
    19 Aug 2013, 02:18 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: